Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Juno Therapeutics, Inc. (JUNO) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/06/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
02/01/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Tax Reimbursement Agreement"
01/22/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Juno Therapeutics Inc., Celgene Corporation and Blue Magpie Corporation",
"Agreement and Plan of Merger, by and among Juno Therapeutics Inc., Celgene Corporation and Blue Magpie Corporation"
01/22/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 22, 2018 Juno Therapeutics, Inc. Delaware 001-36781 46-3656275 400 Dexter Avenue North, Suite 1200 Seattle, Washington 98109 582-1600 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY"
11/09/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/01/2017 8-K Quarterly results
10/20/2017 8-K Quarterly results
09/22/2017 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Underwriting Agreement by and among Juno Therapeutics, Inc., Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC",
"Share Purchase Agreement and Omnibus Amendment by and between Juno Therapeutics, Inc., Celgene Corporation and certain of its affiliates"
08/03/2017 8-K Quarterly results
Docs: "JUNO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS"
06/20/2017 8-K Form 8-K - Current report
05/24/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
04/19/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
09/13/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Juno Therapeutics, Inc. Corporate Presentation - September 2016"
08/26/2016 8-K Resignation/termination of a director
08/04/2016 8-K Form 8-K - Current report
07/13/2016 8-K Form 8-K - Current report
07/07/2016 8-K Form 8-K - Current report
06/17/2016 8-K Form 8-K - Current report
06/07/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Juno Therapeutics, Inc. Corporate Presentation - June 2016"
05/09/2016 8-K Form 8-K - Current report
04/27/2016 8-K Entry into a Material Definitive Agreement
04/01/2016 8-K Form 8-K - Current report
03/28/2016 8-K Form 8-K - Current report
03/08/2016 8-K Form 8-K - Current report
02/29/2016 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "JUNO THERAPEUTICS REPORTS FOURTH QUARTER AND 2015 FINANCIAL RESULTS — On track for approval of JCAR015 as soon as 2017 in relapsed/refractory adult ALL — — First clinical milestone met for CD22 CAR T Cell Product Candidate — — Multiple trials enrolling using CAR/TCR product candidates to treat solid organ tumors — — Celgene collaboration off to a strong start — — Strong 2015 year end cash position of $1.22 billion — — 2016 cash burn guidance of $220 million to $250 million, with $170 million to $195 million in operating burn — — Conference call to be held today at 5:00pm Eastern Time"
02/04/2016 8-K Form 8-K - Current report
01/11/2016 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. AGREEMENT AND PLAN OF REORGANIZATION",
"Juno Therapeutics Adds Next-Generation Single Cell Sequencing Capabilities Through Acquisition of AbVitro — Transaction Accelerates Discovery Capabilities for Fully-Human TCR and CAR Binder Generation, Novel Target Discovery, and Translational Research — — Payment of Approximately $78 Million in Cash and 1,289,193 Shares of Juno Stock — — Agreement in Principle to License Certain AbVitro Technology Rights and Grant Certain Product Option Rights to Celgene — SEATTLE, WA - January 11, 2016 — Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired AbVitro, Inc., a privately held biotechnology company based in Boston, Massachusetts. The acquisition provides Juno with a l...",
"Juno Therapeutics, Inc. Corporate Presentation - January 2016"
12/23/2015 8-K Unregistered Sales of Equity Securities
11/10/2015 8-K Quarterly results
Docs: "JUNO THERAPEUTICS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS — Company-wide progress in advancing product candidates and building capabilities — — Conference call to be held today at 5:00pm Eastern Time"
09/15/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Juno Therapeutics, Inc. Corporate Presentation - September 2015"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy